Any representation to the contrary is a criminal offense.Our Executive Chairman, Alan Gold, may purchase up to 120,000 shares of the Series A Preferred Stock in this offering at the public offering price.The underwriters may also purchase up to an additional 90,000 shares of the Series A Preferred Stock from us at the public offering price, less the underwriting discount, within 30 days from the date of this prospectus solely to cover over-allotments, if any.The underwriters expect to deliver the Series A Preferred Stock through the facilities of The Depositary Trust Company on or about            , 2017, which is the fifth business day following the pricing of this offering.Joint Book Running ManagersLadenburg ThalmannNational Securities CorporationThe date of this prospectus is            , 2017.TABLE OF CONTENTS​TABLE OF CONTENTS​​​Page​FORWARD-LOOKING STATEMENTS​​​​ii​​INCORPORATION BY REFERENCE​​​​iv​​PROSPECTUS SUMMARY​​​​1​​THE OFFERING​​​​6​​RISK FACTORS​​​​12​​USE OF PROCEEDS​​​​17​​CAPITALIZATION​​​​18​​PRO FORMA FINANCIAL INFORMATION​​​​19​​DESCRIPTION OF SERIES A PREFERRED STOCK​​​​21​​DESCRIPTION OF SECURITIES​​​​34​​POLICIES WITH RESPECT TO CERTAIN ACTIVITIES​​​​39​​OUR OPERATING PARTNERSHIP AND THE OPERATING PARTNERSHIPAGREEMENT​​​​42​​SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT​​​​44​​MARKET PRICE OF AND DIVIDENDS ON COMMON STOCK​​​​46​​CERTAIN PROVISIONS OF MARYLAND LAW AND OUR CHARTER AND BYLAWS​​​​47​​MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS​​​​53​​ERISA CONSIDERATIONS​​​​77​​UNDERWRITING​​​​81​​LEGAL MATTERS​​​​85​​EXPERTS​​​​85​​WHERE YOU CAN FIND ADDITIONAL INFORMATION​​​​85​​You should rely only on the information contained in or incorporated by reference into this prospectus, any free writing prospectus prepared by us or information to which we have referred you.
The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:•use of proceeds of this offering;​•our business and investment strategy;​•our projected operating results;​•actions and initiatives of the U.S. or state governments and changes to government policies and the execution and impact of these actions, initiatives and policies, including the fact that cannabis remains illegal under federal law;​•availability of suitable investment opportunities in the medical-use cannabis industry;​•concentration of our portfolio of assets and limited number of tenants;​•our understanding of our competition and our potential tenants’ alternative financing sources;​•the estimated growth in and evolving market dynamics of the medical-use cannabis market;​•the demand for medical-use cannabis cultivation and processing facilities;​•the expected medical-use or adult-use cannabis legalization in certain states;​•shifts in public opinion regarding medical-use cannabis;​•the state of the U.S. economy generally or in specific geographic areas;​•economic trends and economic recoveries;​•our ability to access equity or debt capital;​•financing rates for our target assets;​•our expected leverage;​•changes in the values of our assets;​•our expected portfolio of assets;​•our expected investments;​•interest rate mismatches between our target assets and our borrowings used to fund such investments;​•changes in interest rates and the market value of our target assets;​•rates of default on leases for our target assets;​•the degree to which any interest rate or other hedging strategies may or may not protect us from interest rate volatility;​​iiTABLE OF CONTENTS•impact of and changes in governmental regulations, tax law and rates, accounting guidance and similar matters;​•our ability to qualify as a REIT and, once qualified, maintain our qualification as a REIT for U.S. federal income tax purposes;​•our ability to maintain our exemption from registration under the Investment Company Act of 1940 (the “Investment Company Act”);​•availability of qualified personnel;​•and market trends in our industry, interest rates, real estate values, the securities markets or the general economy.​Any forward-looking statement made by us speaks only of the date on which we make it.
You should read the entire prospectus and the documents incorporated by reference herein, including the section entitled “Risk Factors” herein, in our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q, as well as our financial statements and related notes incorporated by reference herein, before deciding to invest in shares of the Series A Preferred Stock.Unless indicated otherwise, the information included in this prospectus assumes no exercise of the underwriters’ option to purchase up to 90,000 additional shares of the Series A Preferred Stock to cover overallotments, if any.Unless the context otherwise requires or indicates, references in this prospectus to “we,” “us,” “our,” and “our company” refer to Innovative Industrial Properties, Inc., a Maryland corporation, together with its subsidiaries, includingIIP Operating Partnership, LP, a Delaware limited partnership (our “Operating Partnership”), of which we are the sole general partner and through which we conduct our business.Our CompanyWe are a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities.
If, prior to the Change of Control/Delisting Conversion Date (as hereinafter defined), we have provided or provide notice of our election to redeem the Series A Preferred Stock (whether pursuant to our optional redemption right or our special optional redemption right), the holders of Series A Preferred Stock will not have the conversion right described below with respect to the shares of Series A Preferred Stock subject to such notice.A “Change of Control/Delisting” is when, after the original issuance of the Series A Preferred Stock, any of the following has occurred and is continuing:•the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), of beneficial ownership, directly or indirectly, through a purchase, merger or​​7TABLE OF CONTENTSother acquisition transaction or series of purchases, mergers or other acquisition transactions of stock of our company entitling that person to exercise more than 50% of the total voting power of all stock of our company entitled to vote generally in the election of our directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and•following the closing of any transaction referred to in the bullet point above, neither we nor the acquiring or surviving entity has a class of common securities (or American Depositary Receipts (“ADRs”) representing such securities) listed on the NYSE, the NYSE American LLC (“NYSE American”) or the NASDAQ Stock Market (“NASDAQ”), or listed or quoted on an exchange or quotation system that is a successor to the NYSE, the NYSE American or NASDAQ.​Conversion Right Upon a Change of Control/DelistingUpon the occurrence of a Change of Control/Delisting, each holder of Series A Preferred Stock will have the right (unless, prior to the Change of Control/Delisting Conversion Date, we have provided or provide notice of our election to redeem the Series A Preferred Stock) to convert some or all of such holder’s shares of Series A Preferred Stock (the “Change of Control/​Delisting Conversion Right”) on the Change of Control/Delisting Conversion Date into a number of shares of our common stock per share of Series A Preferred Stock to be converted, which is equal to the lesser of:•the quotient obtained by dividing (i) the sum of  (x) the liquidation preference amount of  $25.00 per share of Series A Preferred Stock, plus (y) the amount of any accrued but unpaid dividends (whether or not declared) to, but not including, the Change of Control/Delisting Conversion Date (unless the Change of Control/​Delisting Conversion Date is after a record date for a Series A Preferred Stock dividend payment and prior to the corresponding Series A Preferred Stock dividend payment date, in which case no additional amount for such accrued but unpaid dividend will be included in this sum) by (ii) the Common Stock Price (as hereinafter defined); and​•(the “Share Cap”), subject to certain adjustments;​subject, in each case, to provisions for the receipt of alternative consideration as described in this prospectus.If, prior to the Change of Control/Delisting Conversion Date, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right in connection with a Change of Control/Delisting or our optional redemption right,8TABLE OF CONTENTSholders of Series A Preferred Stock will not have any right to convert the Series A Preferred Stock in connection with the Change of Control/Delisting Conversion Right and any shares of Series A Preferred Stock selected for redemption that have been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Change of Control/​Delisting Conversion Date.For definitions of  “Change of Control/Delisting Conversion Date” and “Common Stock Price,” and for a description of the adjustments and provisions for the receipt of alternative consideration that may be applicable to the Change of Control/​Delisting Conversion Date, see “Description of Series A Preferred Stock — Conversion Right Upon a Change of Control/​Delisting.”Except as provided above in connection with a Change of Control/Delisting, the Series A Preferred Stock is not convertible into or exchangeable for any other securities or property.Limited Voting RightsHolders of shares of the Series A Preferred Stock will generally have no voting rights.
However, if dividends on the Series A Preferred Stock are in arrears for six or more quarterly periods, whether or not consecutive, the number of directors then constituting our board of directors will be increased by two, and holders of shares of the Series A Preferred Stock (voting separately as a single class together with the holders of the Parity Preferred Stock upon which like voting rights have been conferred and are exercisable (the “Voting Preferred Stock”)) will be entitled to vote, at a special meeting called upon the written request of the holders of at least 10% of such stock or at our next annual meeting and at each subsequent annual meeting of stockholders, for the election of two additional directors to serve on our board of directors (the “Preferred Directors”) until all unpaid dividends with respect to the Series A Preferred Stock and the Parity Preferred Stock have been paid.In addition, the affirmative vote or consent of the holders of at least two-thirds of the outstanding shares of the Series A Preferred Stock, and the Voting Preferred Stock (voting together as a single class), is required for us to authorize or issue any class or series of capital stock ranking, as to payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, senior to the Series A Preferred Stock or to amend any provision of our charter so as to materially and adversely affect the terms of the Series A Preferred Stock.